Genalumab for children with active systemic juvenile arthritis
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is age 2 to under 18 years old
- Your child has confirmed systemic juvenile idiopathic arthritis (sJIA) for at least 2 months
- Your child has ongoing active disease with joint inflammation plus recurrent fevers and other listed symptoms (like rash, swollen lymph nodes, enlarged liver/spleen, or inflammation around the heart/lungs)
- If your child can become pregnant or father a child, they must use reliable birth control during the study and for 6 months after
- Your child must not be pregnant or breastfeeding
- Your child must not have recent serious heart/lining inflammation (like pericarditis or myocarditis) or recent suspected/diagnosed MAS (macrophage activation syndrome)
- Your child must not have certain lung problems or recent significant infections, and must not have signs of tuberculosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis who haven't improved enough after trying at least one standard arthritis medication. The goal is to see if this treatment can help reduce joint pain and swelling.
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Hear when a new Active Systemic Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.